These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23611600)

  • 21. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
    Ricotta DN; Frishman W
    Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mipomersen and its use in familial hypercholesterolemia.
    Parham JS; Goldberg AC
    Expert Opin Pharmacother; 2019 Feb; 20(2):127-131. PubMed ID: 30526168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia.
    Haddley K
    Drugs Today (Barc); 2011 Dec; 47(12):891-901. PubMed ID: 22348914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
    McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
    PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
    Patel RS; Scopelliti EM; Savelloni J
    Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia.
    Brown WV; Rader DJ; Goldberg AC
    J Clin Lipidol; 2014; 8(1):10-7. PubMed ID: 24528683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
    Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging options in the treatment of dyslipidemias: a bright future?
    Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):247-70. PubMed ID: 21323473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study.
    Nohara A; Otsubo Y; Yanagi K; Yoshida M; Ikewaki K; Harada-Shiba M; Jurecka A
    J Atheroscler Thromb; 2019 Apr; 26(4):368-377. PubMed ID: 30259883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.
    Blom DJ; Cuchel M; Ager M; Phillips H
    Orphanet J Rare Dis; 2018 Jun; 13(1):96. PubMed ID: 29925433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.
    Santos RD; Duell PB; East C; Guyton JR; Moriarty PM; Chin W; Mittleman RS
    Eur Heart J; 2015 Mar; 36(9):566-75. PubMed ID: 24366918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials.
    Panta R; Dahal K; Kunwar S
    J Clin Lipidol; 2015; 9(2):217-25. PubMed ID: 25911078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
    Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New pharmacologic treatments for familial hypercholesterolemia.
    McDonough A; Matura LA; Carroll D
    Nurs Womens Health; 2013 Oct; 17(5):443-7. PubMed ID: 24138664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia.
    Harada-Shiba M; Ikewaki K; Nohara A; Otsubo Y; Yanagi K; Yoshida M; Chang Q; Foulds P
    J Atheroscler Thromb; 2017 Apr; 24(4):402-411. PubMed ID: 28154305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.